Please assess the completion status of the following clinical trial:

Trial Title: A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in Patients With Schizophrenia. RESPECT Study.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Female and male patients ≥ 18 years of age.~2. Patients with schizophrenia based on the Diagnostic of Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).~3. Patients currently treated with oral SGA monotherapy for a minimum of 3 months that are prescribed\* to switch to another oral SGA medication. Patients will be included in a cohort depending on the switching treatment prescribed:~   * Cohort A: patients who are prescribed to switch to lurasidone (lurasidone cohort)~  * Cohort B: patients who are prescribed to switch to any other monotherapy SGA (other SGA cohort) \*Treatment switch and overlap period will be performed according to clinical practice and medical criteria.~4. Written informed consent prior to participation.~Exclusion Criteria:~1. Patients with a known cardiovascular disease or suspected of having a heart disease.~2. Pregnant or breastfeeding women.~3. Patients diagnosed with at least one of the following: depression with psychotic symptoms, schizoaffective disorder, bipolar disorder or organic brain syndromes; Patients with active suicidal ideation or patients who have habitual and sustained consumption of alcohol and / or other toxic substances are also excluded.~4. Patients who had been treated with a long-acting within the last 6 months, or within last year in case of Trevicta®.~5. Concomitant treatments with antipsychotics for insomnia or anxiety (i.e., low doses of quetiapine, etumine, levomepromazine or similar). Concomitant treatment with sedative substances not considered antipsychotics (i.e., benzodiazepines or similar) when they are being taking regularly and at unchanged low doses are allowed.~6. Patients with history of seizures, stroke, neuroleptic malignant syndrome or epilepsy are excluded.~7. Current participation in any clinical trial.~8. Patients for whom further follow-up is not possible at the enrolling site.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: None): Patients who are prescribed to switch to lurasidone (lurasidone cohort)
- B (Type: None): Patients who are prescribed to switch to any other monotherapy SGA (other SGA cohort)

Based on this trial design, predict the completion outcome and termination type (if applicable).